Salud financiera de hoja de balance de Vertex Pharmaceuticals
Salud financiera controles de criterios 6/6
Vertex Pharmaceuticals tiene un patrimonio de accionistas total de $17.6B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $22.7B y $5.1B respectivamente. El BAIT de Vertex Pharmaceuticals es de $4.3B, por lo que su ratio de cobertura de intereses es de -7.5. Tiene efectivo e inversiones a corto plazo que ascienden a $11.2B.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | -7.5x |
| Efectivo | US$11.22b |
| Patrimonio | US$17.58b |
| Total pasivo | US$5.15b |
| Activos totales | US$22.73b |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05
Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued
Jan 23If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jan 02Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?
Oct 24Vertex to advance two AAT correctors to potentially treat rare, genetic disease
Oct 11Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?
Oct 02Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate
Sep 28Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook
Sep 19Vertex wins FDA label expansion for cystic fibrosis drug to add younger children
Sep 02Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($14.1B) de VRTX superan a sus pasivos a corto plazo ($3.5B).
Pasivo a largo plazo: Los activos a corto plazo de VRTX ($14.1B) superan a sus pasivos a largo plazo ($1.6B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: VRTX está libre de deudas.
Reducción de la deuda: VRTX no tenía deudas hace 5 años.
Cobertura de la deuda: VRTX no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: VRTX no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.